EHU089041
MISSION® esiRNA
targeting human USP4
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.51
UNSPSC Code:
41105324
description
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
GGGACAGTGAAACTCGGAGACTTTACTATGATGAGCAAGAATCTGAGGCCTACGAGAAGCATGTGAGCATGTTGCAGCCTCAGAAGAAGAAGAAGACCACAGTGGCCCTGAGAGACTGCATCGAGCTCTTCACCACCATGGAGACCCTTGGGGAGCATGACCCCTGGTACTGTCCCAACTGTAAGAAGCATCAACAGGCCACAAAAAAGTTTGACCTATGGTCCTTGCCCAAGATCCTGGTGGTCCACCTCAAACGTTTCTCCTACAACAGATACTGGAGGGATAAGCTCGACACAGTCGTAGAATTCCCAATCAGAGGGCTGAACATGTCCGAGTTTGTCTGTAACCTGTCAGCAAGGCCTTATGTGTACGACCTCATTGCCGTGTCCAATCATTATGGAGCCATGGGGGTTGGCCACTACACTGCAT
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
human ... USP4(107986084), USP4(7375)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Na Qin et al.
Oncology letters, 17(1), 958-964 (2019-01-19)
Glioblastoma is a malignant primary brain tumor with poor prognosis with a median survival of only 12-15 months. The high mortality rate of this disease is mainly due to the chemoresistance resulting from various reasons. Ubiquitin-specific protease 4 (USP4) has
Jie Zhang et al.
Molecular medicine reports, 20(2), 1429-1435 (2019-06-08)
Pathological scarring is a result of the hypertrophy of scar tissue during tissue repair following trauma. The aim of the present study was to assess the effect of ubiquitin‑specific protease 4 (USP4) silencing on pathological scarring, and to evaluate the
Global Trade Item Number
| SKU | GTIN |
|---|---|
| EHU089041-20UG | 04061831355260 |
| EHU089041-50UG | 04061828398393 |